

Easing the Tension: A Multidisciplinary Approach to Pulmonary Hypertension

Emily Erusalsky, MD¹, Marcia Chen, MD¹, Joe Bryant-Huppert, MD¹

¹Department of Anesthesiology, Weill Cornell Medical College, New York, NY

Background

- Pulmonary hypertension (PH) is characterized by elevated (>20 mmHg) pulmonary arterial pressure (PAP) and pulmonary vascular resistance (PVR)
- Incidence: 1% of the global population
- Maternal mortality rates of 30-50% due to poor tolerance of the physiological change (e.g., increased plasma volume and cardiac output)
- Pregnancy is contraindicated in PH due to the high risk of maternal cardiac events
- Despite counseling, patients with PH may elect to continue their pregnancies




Figure 1. Pathophysiology of cardiovascular collapse in pregnant patients with PH during pregnancy. SVR: systemic vascular resistance; PVR: pulmonary vascular resistance. (Phoophiboon 2021)

Table 1. Clinical classification of pulmonary hypertension

Classification	Targeted treatment available?
Group 1*: Pulmonary arterial hypertension Including idiopathic, heritable, and HIV-associated; systemic sclerosis and other connective tissue disease; congenital heart disease; schistosomiasis; drug- and toxin-induced	Yes
Group 2: Pulmonary hypertension due to left heart disease Including systolic and diastolic dysfunction and valvular heart disease	No
Group 3: Pulmonary hypertension due to lung diseases and/or hypoxia Including chronic obstructive pulmonary disease, sleep-disordered breathing, and interstitial lung disease	No
Group 4: Chronic thromboembolic pulmonary hypertension	Yes
Group 5: Multifactorial pulmonary hypertension Including metabolic, systemic, and hematologic disorders (sickle cell disease), and others	No

HIV = human immunodeficiency virus.

*—Also includes 1' (pulmonary venoocclusive disease and/or pulmonary capillary hemangiomatosis) and 1" (persistent pulmonary hypertension of the newborn).

Information from references 3, 4, and 6.

Easing the Tension: A Multidisciplinary Approach to Pulmonary Hypertension

Emily Erusalsky, MD¹, Marcia Chen, MD¹, Joe Bryant-Huppert, MD¹

¹Department of Anesthesiology, Weill Cornell Medical College, New York, NY



Case

- 31F G2P0010 at 33 weeks 2 days gestational age with PH as a sequelae of severe obstructive sleep apnea, obesity hypoventilation syndrome, and chronic thromboembolic disease was diagnosed with pre-eclampsia with severe features (PEC with SF) in triage
 - Other medical history: hypertension, asthma, morbid obesity (BMI 55), type 2 diabetes mellitus
 - TTE: normal left ventricular size and function, dilated right ventricle, mild PH
 - Right Heart Catheterization (RHC): PAP 53/25, mean PAP 34
- Monitors: standard ASA monitors and pre-induction arterial line
- Anesthetic: prophylactic vasopressin prior to CSE at L3-4 with 1cc 0.75% bupivacaine-8.25% dextrose, 15mcg fentanyl, and 0.15mg morphine; epidural slowly dosed with 8cc 2% lidocaine-1:200,000 epinephrine
- High flow nasal cannula, titrated to PaO₂
- Infusions: magnesium for PEC with SF, insulin for hyperglycemia
- Pitocin initiated after delivery of anterior shoulder
- Transferred to cardiac intensive care unit for recovery
 - Required diuresis for worsening PH and volume overload
- Discharged post-op day 7, with resolution of PH on RHC




Figure 2. Intraoperative anesthetic record of the patient's Cesarean delivery

Easing the Tension: A Multidisciplinary Approach to Pulmonary Hypertension

Emily Erusl, MD¹, Marcia Chen, MD¹, Joe Bryant-Huppert, MD¹

¹Department of Anesthesiology, Weill Cornell Medical College, New York, NY



Discussion

- Recent studies have shown a decline in maternal mortality among pregnant women with well controlled PH, ranging 9-25%¹
- Management: supplemental oxygen, diuretics, and anticoagulation. Targeted therapy may include endothelin receptor antagonists, prostacyclin analogs, and phosphodiesterase-5 inhibitors
- CD preferred over labor to avoid acute increases in PVR
- Neuraxial anesthesia preferred over general anesthesia
- ICU should be available for recovery
- Contingency planning for acute decompensation: central access with pulmonary artery catheter (PAC) placement, escalation of respiratory support, inotropic support, and pulmonary dilators
- Multidisciplinary planning between maternal fetal medicine, obstetric anesthesiology, cardiology, and neonatology is imperative for safe delivery

3 rd trimester without labour pain	Peri-partum stage	Post-partum stage
Multidisciplinary team approach Obstetrician, cardiologist, intensivist pulmonologist, anaesthesiologist, cardio-thoracic surgeon, paediatrician	Delivery and anesthesia	Hemodynamic monitoring
PAH-targeted therapy (Pregnancy category) B: Epoprostenol, Treprostinil, Sildenafil C: Nitric oxide, Iloprost X: Endothelin receptor antagonist, Soluble guanylate cyclase stimulator	✓ Delivery at GA 32-36 weeks ✓ Prefer Caesarean section ✓ Combination of spinal and epidural approach X Avoid general anesthesia or single-dose spinal anesthesia (profound hypotension, increase intrathoracic pressure)	✓ Close monitoring in intensive care unit
Others ✓ Close monitoring: TTE, arterial line, central venous catheter (routine PAC is not recommended) ✓ Anticoagulant: LMWH, Heparin	Others ✓ Standby: ECMO(VA), inhaled nitric oxide, inotropic drugs, ✓ Minimize dose of oxytocin infusion X Avoid ergotamine and prostaglandin F2 alpha (pulmonary vasoconstriction)	PAH-targeted therapy ✓ Continue and adjust PAH-targeted therapy
		Others ✓ Consider ECMO(VA), atrial septostomy X Right ventricular assist device ✓ Transplant listing

Figure 3. Critical care management for pregnant patients with pulmonary arterial hypertension (PAH) TTE: transthoracic echocardiography; LMWH: low molecular weight heparin; ECMO: extracorporeal membrane oxygenation; VA: veno-arterial. (Phoophiboon 2021)

References

1. Afify H et al. Integr Blood Press Control 2022. PMID: 35401013; PMCID: PMC8985908.
2. Dunlap B et al. Am Fam Physician. PMID: 27637122.
3. Hemnes AR et al. Pulm Circ. 2015. PMID: 26401246
4. Krishnan, S et al. Current Pulmonology Reports. 10. 10.1007/s13665-021-00275-1.
5. Thomas E et al. JAHA. 2017. PMID: 29066439
6. Phoophiboon V et al. Acute Crit Care. 2021;36(4):286-293. doi: 10.4266/acc.2021.00458